Only SAPIEN 3 TAVR is proven superior to surgery in low-risk patients1

PARTNER 3 Low-Risk Trial

*As defined in the PARTNER 3 trial: valve related, procedure related, cardiac related rehospitalization.

**More death and stroke events in TAVR patients from 1 to 2 years; no significant differences at 2 years.

These endpoints were not subject to multiplicity adjustment.

Differentiated outcomes start with differentiated design

The SAPIEN 3 Ultra valve is built on the proven SAPIEN 3 platform.

Edwards Commander delivery system

Predictability and control to meet the increasing complexity of your procedures.

0.6%1
stroke rate at
30 days in
low risk patients
99%4
deployment
accuracy

Single-digit new permanent pacemaker rates in low-risk patients1

6.5%
at 30 days
7.3%
at 1 year

References:   1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. 2. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. JACC 2021; 779(9):1149-1161. 3. Nazif T, Daniels D, McCabe J, Chehab B, et al. Real-world experience with the SAPIEN 3 Ultra TAVR: A propensity matched analysis from the United States. Presented virtually at TVT Connect 2020.​ 4. PARTNER II Trial intermediate-risk cohort 30-day unadjusted clinical event rates for TAVR with the SAPIEN 3 valve, AT population (n=1077).